文章：

急性髓系白血病中利用抗体或CAR-T细胞靶向膜抗原

Membrane Antigen Targeting in Acute Myeloid Leukemia Using Antibodies or CAR-T Cells

原文发布日期：28 October 2024

DOI: 10.3390/cancers16213627

类型: Article

开放获取: 是

英文摘要：

This review explores the emerging area of the therapeutic use of antibodies and chimeric antigen receptor (CAR)-T cells for the treatment of acute myeloid leukemia (AML). Through a detailed analysis of the existing literature, this paper highlights the different categories of AML antigens for immunotherapeutic targeting, the most recent applications on antibodies, including bispecific immune cell engagers and CAR-T cells, to the therapy of patients with refractory/relapsing AML The studies performed in AML patients using BisAbs and CAR-T cells have shown that only a limited number of AML patients show sustained responses to these therapies, thus underlying AML heterogeneity as a major challenge. Several studies have addressed the potential mechanisms underlying the resistance of AMLs to antibody-directed immunotherapies. A better understanding of the barriers hampering the successful development of AML immunotherapy is required. However, in spite of the limitations, the studies recently carried out have shown the peculiar sensitivity of some AML subtypes to immunotherapy and have provided the basis for future studies, such as multiplex antigen targeting, which hold the promise of successful development.

摘要翻译： 

本综述探讨了抗体及嵌合抗原受体（CAR）-T细胞在急性髓系白血病（AML）治疗中这一新兴领域。通过对现有文献的详细分析，本文重点阐述了免疫治疗靶向的AML抗原不同类别，以及双特异性免疫细胞衔接器和CAR-T细胞在难治性/复发性AML患者治疗中的最新应用。针对AML患者使用双特异性抗体和CAR-T细胞的研究表明，仅有少数AML患者对这些疗法表现出持续应答，这凸显了AML异质性作为主要治疗挑战的现实。多项研究已探讨AML对抗体导向免疫疗法产生耐药的潜在机制。当前亟需更深入理解阻碍AML免疫疗法成功开发的障碍。尽管存在局限性，近期研究仍揭示了特定AML亚型对免疫疗法的独特敏感性，并为未来研究（如多抗原靶向治疗等具有成功开发前景的方向）奠定了理论基础。

原文链接：

Membrane Antigen Targeting in Acute Myeloid Leukemia Using Antibodies or CAR-T Cells